December 4, 2025

Single enzyme failure found to drive neuron loss in dementia

December 4, 2025 / Research update / InnovateMed Author / dementia

Peer-Reviewed Publication Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)) Researchers at Helmholtz Munich, the Technical University of Munich and the LMU University Hospital Munich uncovered a mechanism that protects nerve cells from premature cell death, known as ferroptosis. The study provides the first molecular evidence that ferroptosis can drive neurodegeneration […]

Single enzyme failure found to drive neuron loss in dementia Read More »

A simple urine test could revolutionize bladder cancer diagnosis and treatment

December 4, 2025 / Research update / InnovateMed Author / bladder cancer

Groundbreaking study published in The Journal of Molecular Diagnostics paves the way for noninvasive screening tools that improve patient comfort and outcomes Peer-Reviewed Publication Elsevier image: Groundbreaking research in The Journal of Molecular Diagnostics shows that analysis of specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer.

A simple urine test could revolutionize bladder cancer diagnosis and treatment Read More »

MD Anderson shares latest research breakthroughs

December 4, 2025 / News update / InnovateMed Author / research breakthroughs

Peer-Reviewed Publication University of Texas M. D. Anderson Cancer Center FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail HER2-targeted therapy showed durable and clinically meaningful results for patients with rare bile duct cancers Researchers identified promising therapeutic targets for KRAS-mutant cancers and kidney cancers Study provides insights into AI models for genomic analysis and clinical decision-making Researchers uncovered how DNA shape and rigidity

MD Anderson shares latest research breakthroughs Read More »

FDA approves updated label for Unloxcyt

December 4, 2025 / Clinical Practice / InnovateMed Author / unloxcyt

by Lori Solomon edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. The updated label incorporates long-term

FDA approves updated label for Unloxcyt Read More »

New tool can help concussion patients manage fear and improve recovery

December 4, 2025 / Clinical Practice / InnovateMed Author / concussion

by Edith Cowan University edited by Sadie Harley, reviewed by Andrew Zinin Editors’ notes Credit: Edward Jenner from Pexels Researchers from Edith Cowan University (ECU) have developed a new tool to evaluate fear avoidance behavior following a concussion. The tool, aptly named the Fear Avoidance after Concussion Tool (FACT), consists of a questionnaire that can be completed within

New tool can help concussion patients manage fear and improve recovery Read More »

Flu season has started early this year—a new variant might be to blame

December 4, 2025 / Patient education / InnovateMed Author / flu

by Ignacio López-Goñi, The Conversation edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes Credit: Andrea Piacquadio from Pexels Every winter, respiratory viruses, especially influenza, SARS-CoV-2 and RSV, put huge pressure on health care systems throughout Europe. In a typical season, flu causes up to 50 million symptomatic cases, and anywhere from 15,000 to 70,000 deaths per year on the

Flu season has started early this year—a new variant might be to blame Read More »

Experimental drug repairs DNA damage caused by common diseases

December 4, 2025 / Research update / InnovateMed Author / DNA damage

by Cedars-Sinai Medical Center edited by Stephanie Baum, reviewed by Robert Egan Editors’ notes Credit: CC0 Public Domain Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of medications that fix tissue damage caused by heart attack, inflammatory disease or other conditions. Investigators describe the workings of the

Experimental drug repairs DNA damage caused by common diseases Read More »

Sneaky senescent cells that resist cancer treatment can provide druggable lung cancer target

December 4, 2025 / Research update / InnovateMed Author / lung cancer

by University of California, San Francisco edited by Lisa Lock, reviewed by Robert Egan Editors’ notes Credit: Cell Stem Cell (2025). DOI: 10.1016/j.stem.2025.10.005 Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone by since cell biologist Judith Campisi, Ph.D., paradoxically demonstrated that these same cells can promote cancer growth in

Sneaky senescent cells that resist cancer treatment can provide druggable lung cancer target Read More »

Millions of Abbott glucose sensors recalled after faulty readings linked to deaths

December 4, 2025 / Patient education / InnovateMed Author / abbott glucose

by I. Edwards edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes Millions of people rely on continuous glucose monitors to help manage diabetes. But a new alert from the U.S. Food and Drug Administration (FDA) warns that some sensors from Abbott may give incorrect blood sugar readings, which could lead to unsafe treatment decisions. The issue affects

Millions of Abbott glucose sensors recalled after faulty readings linked to deaths Read More »

New bioadhesive strategy can prevent fibrous encapsulation around device implants on peripheral nerves

December 4, 2025 / Research update / InnovateMed Author / implant

by Anne Wilson, Massachusetts Institute of Technology edited by Lisa Lock, reviewed by Robert Egan Editors’ notes Caption:Bioelectronic devices implanted on peripheral nerves often trigger the formation of dense fibrotic tissue at the device–tissue interface, but with the new bioadhesive strategy, the interface stayed immunologically pristine for up to 12 weeks. Credit: Massachusetts Institute of Technology Peripheral nerves—the

New bioadhesive strategy can prevent fibrous encapsulation around device implants on peripheral nerves Read More »